Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application ...
Sanofi has recently got the US Food and Drug Administration for a supplemental biologic licence application for Tzield, ...
The U.S. Food and Drug Administration has approved a supplemental biologics license application for Sanofi’s (SNY) Tzield ...
The FDA has approved an expanded indication for the CD3-directed monoclonal antibody teplizumab-mzwv to delay stage 3 type 1 ...
The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval ...
Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision by the U.S. Food and Drug Administration (FDA) to approve Sanofi ...
Teplizumab-mzwv is the first disease-modifying therapy available for children as young as 1 year diagnosed with ...
The US Food and Drug Administration (FDA) has approved Sanofi’s supplemental biologic license application for Tzield ...
RED BANK, N.J., Nov. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results